search button
Open Access

Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report

  • Authors:
    • Masayuki Sano
    • Shinya Yamamoto
    • Sho Uehara
    • Takeshi Yuasa
    • Hitoshi Masuda
    • Iwao Fukui
    • Junji Yonese

  • View Affiliations

  • Published online on: July 1, 2016     https://doi.org/10.3892/mco.2016.946
  • Pages: 208-210

  • Copyright: © Sano et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Antiandrogen withdrawal syndrome (AWS) is a well-established phenomenon in prostate cancer treated with combined androgen blockade (CAB). AWS is generally defined as subjective and/or objective improvement following discontinuation of an antiandrogen. However, the duration of the AWS response is usually limited. In addition, a complete response is quite rare. We herein present the case of a patient who achieved complete response from AWS, with the duration of this response lasting for >6 years. A 72‑year‑old man with metastatic prostate cancer received CAB with a luteinizing hormone‑releasing hormone analog and bicalutamide. In addition, for local cancer control, external beam radiation therapy (70 Gy) to the prostate was performed. Subsequently, the serum prostate‑specific antigen (PSA) level reached a nadir (undetectable level). Four years later, the patient's serum PSA level started to rise, and bicalutamide was discontinued to confirm AWS at a serum PSA level of 0.34 ng/ml. The PSA level immediately decreased again to an undetectable level (0.00 ng/ml), where it has been remained for 6 years. Bone scintigraphy and computed tomography scans have shown no evidence of bone or other metastases since the introduction of AWS. To the best of our knowledge, there have been no reports of such a long duration of complete response from AWS. Therefore, this phenomenon should always be considered, even in patients with advanced disease.
View Figures
View References

Related Articles

Journal Cover

September-2016
Volume 5 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.4
  • Ranked
    (total number of cites)
  • CiteScore: 2.8
  • CiteScore Rank: Q3: #250/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.55
  • SCImago Journal Rank (SJR): 0.446
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Sano M, Yamamoto S, Uehara S, Yuasa T, Masuda H, Fukui I and Yonese J: Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report. Mol Clin Oncol 5: 208-210, 2016.
APA
Sano, M., Yamamoto, S., Uehara, S., Yuasa, T., Masuda, H., Fukui, I., & Yonese, J. (2016). Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report. Molecular and Clinical Oncology, 5, 208-210. https://doi.org/10.3892/mco.2016.946
MLA
Sano, M., Yamamoto, S., Uehara, S., Yuasa, T., Masuda, H., Fukui, I., Yonese, J."Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report". Molecular and Clinical Oncology 5.3 (2016): 208-210.
Chicago
Sano, M., Yamamoto, S., Uehara, S., Yuasa, T., Masuda, H., Fukui, I., Yonese, J."Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report". Molecular and Clinical Oncology 5, no. 3 (2016): 208-210. https://doi.org/10.3892/mco.2016.946